Giovanna Quatrale

Dr. Giovanna Quatrale

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
VGValentina Giorgio
Valentina Giorgio
GQGiovanna Quatrale
Giovanna Quatrale
MMMaurizio Mennini
Maurizio Mennini
MPMarisa Piccirillo
Marisa Piccirillo
SFSilvia Furio
Silvia Furio
Giovanni Di NardoGiovanni Di Nardo
Giovanni Di Nardo
The gut microbiota plays a pivotal role in gastrointestinal inflammation and immune response since changes in microbiota may result in abnormal neurotransmitter expression, inducing changes in gastrointestinal sensory–motor function and leading to symptom onset in irritable bowel syndrome (IBS) patients. The Bifidobacterium adolescentis species has a documented immunomodulatory effect through its ability to produce γ-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the mammalian central nervous system, which is reduced in IBS patients. This is a multicentric, randomized, double-blind, placebo-controlled, parallel-arm trial aimed at evaluating the effectiveness of Bifidobacterium adolescentis PRL2019 in children with IBS. IBS children diagnosed according to Rome IV criteria were enrolled and randomized into two groups to receive one stick containing 20 × 109 colony-forming unit of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy) or an equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Clinical evaluation of symptoms was performed every four weeks using validated scores. Bowel habit characteristics were assessed using the Bristol Stool Chart (BSC). Seventy-two subjects (mean age 12.2 ± 1.8 years, 30 males) were enrolled and randomized into two groups, each of thirty-six patients. No significant differences were observed between the two groups regarding demographic characteristics, distribution of IBS subtypes, or baseline measures of IBS severity and BSC. The proportion of patients achieving complete remission was significantly higher in the BA Group (19/36; 52.8%) than in the Placebo Group (7/36; 19.4%, p = 0.003, odds ratio [OR] 0.216, 95% confidence interval [CI] 0.075–0.619). Both groups obtained a reduction in Total IBS Symptom Severity Scale (IBS SSS), Pain Intensity Score (PIS), Pain Frequency Score (PFS), and Life Interference Score (LIS) from T0 to T12. However, upon intergroup comparison, only in the BA group did the IBS-SSS (p = 0.001), PIS (p = 0.001), LIS (p = 0.015), and PFS (p = 0.005) significantly improve between T0 and T12. BSC showed a greater representation of normal stools (type 3–4) at the end of treatment in the BA group compared with baseline (25% vs. 58.3%, p = 0.004), especially in patients who presented an IBS–constipation subtype at T0 (44.5% vs. 19.4%, p = 0.02). In our study, Bifidobacterium adolescentis PRL2019 reduces the severity and frequency of symptoms in children with IBS, positively affecting bowel habits in children with the IBS–constipation subtype.

24 September 2025 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
VGValentina Giorgio
Valentina Giorgio
CFChiara Di Foggia
Chiara Di Foggia
GQGiovanna Quatrale
Giovanna Quatrale
GMGaia Margiotta
Gaia Margiotta
GSGiuseppe Stella
Giuseppe Stella
EGEleonora Gaetani
Eleonora Gaetani
Background: Hereditary Hemorrhagic Telangiectasia (HHT) is a rare, hereditary, autosomal dominant vascular disease, characterized by visceral arteriovenous malformations (AVMs), mucocutaneous telangiectasias and epistaxis. While symptomatic medical and surgical therapies are used in the management of pediatric patients, data comparing phenotypic presentation between genetically related individuals (e.g., parent-child pairs) remain limited. Aims and Methods: We conducted a single-center retrospective study involving pediatric patients with genetically confirmed HHT and their affected parents at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, Italy. The aim of our study was to assess genotype-phenotype correlation and intrafamilial HHT-phenotypic variability. Clinical, laboratory, imaging, and therapeutic data were collected between May 2022 and May 2023. Variables including presence of AVMs, epistaxis, telangiectasias, anemia, and need for interventions were compared between children and their parents. Results: The study included 11 children (mean age 11.8 years) and 9 adults (mean age 47 years), all exhibiting ENG or ACVRL1 variants. While epistaxis was common in both cohorts (91% in children vs. 100% in adults), mucocutaneous telangiectasias and AVMs were more prevalent in adults. AVMs were more frequently detected in adults, especially among ENG carriers. Notably, phenotype concordance between parent-child pairs with the same mutation was observed in only 3 up to 9 families (33.3%), with substantial intrafamilial variability in AVM distribution and disease severity. Conclusions: Our findings confirm the variable expressivity of HHT, even among first-degree relatives sharing the same pathogenic variant. No consistent overlap was observed between parent and child phenotypes, reinforcing the need for individualized pediatric screening and follow-up. Early genetic testing remains essential to prevent complications and guide appropriate management.

21 December 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
MPMarisa Piccirillo
Marisa Piccirillo
ERErika Renzi
Erika Renzi
CVCorrado De Vito
Corrado De Vito
MMMaurizio Mennini
Maurizio Mennini
GGGiacomo Giarrusso
Giacomo Giarrusso
Giovanni Di NardoGiovanni Di Nardo
Giovanni Di Nardo
Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction (DGBI), whose exact etiology remains unclear. The “brain–gut-microbiota axis” proved to be a key target in IBS management and there is strong evidence supporting the use of probiotics for improving overall symptoms both in adults and in children. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating the effects of probiotic supplementation in pediatric patients diagnosed with IBS according to Rome III or IV criteria. Scopus, PubMed, and Cochrane Library were the available databases systematically searched up to February 2025. Six RCTs with 604 participants were included in the final systematic review. Three RCTs provided data from which the meta-analysis demonstrated that probiotic supplementation has a significant effect on reducing abdominal pain in patients with IBS (SMD −0.95, 95% CI −1.63 to −0.27). Other three RCTs reported data on the effects on stool consistency, and their meta-analysis proved that supplementation results in stool consistency normalization in patients with diarrhea or constipation (OR 2.17, 95% CI 1.18 to 4). The present meta-analysis demonstrated that probiotic supplementation can reduce abdominal pain in pediatric patients with IBS and provide significant bowel habit normalization in patients with diarrhea or constipation at baseline compared to placebo.

29 September 2026 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
PDF file
GQGiovanna Quatrale
Giovanna Quatrale
MBMarco Bianchi
Marco Bianchi
LCLuigi Colecchia
Luigi Colecchia
VGValentina Giorgio
Valentina Giorgio
MMMaurizio Mennini
Maurizio Mennini
Giovanni Di NardoGiovanni Di Nardo
Giovanni Di Nardo

22 July 2026 in Nutrition
Verified
Journal Article
Closed access
MBMarco Bianchi
Marco Bianchi
GQGiovanna Quatrale
Giovanna Quatrale
LCLuigi Colecchia
Luigi Colecchia
CCCesare Cremon
Cesare Cremon
MPMarisa Piccirillo
Marisa Piccirillo
Giovanni Di NardoGiovanni Di Nardo
Giovanni Di Nardo